Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles

J Med Virol. 2020 Sep;92(9):1609-1614. doi: 10.1002/jmv.25865. Epub 2020 Apr 25.

Abstract

Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans in late 2019, it has rapidly spread worldwide. To identify the biological characteristics of SARS-CoV-2 in a normal laboratory environment (biosafety level 2 [BSL-2]), a lentiviral-based nucleocapsid was used to carry the spike protein of SARS-CoV-2 onto the surface of pseudoviral particles as a surrogate model to evaluate the infective characterization of SARS-CoV-2. This study indicated that SARS-CoV-2 has extensive tissue tropism for humans and may infect monkeys and tree shrews but not rodents. More importantly, the use of pseudoviral particles in this study allows rapid assessment of neutralizing antibodies in serum in a BSL-2 laboratory. This study will provide a quick and easy tool for evaluating neutralizing antibodies in the serum of recovering patients and assessing the potency of candidate vaccines.

Keywords: SARS-CoV-2; infectivity; neutralization; pseudoviral particles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • COVID-19 / immunology
  • COVID-19 / prevention & control
  • COVID-19 / virology*
  • Cell Line
  • Cells, Cultured
  • Genes, Reporter
  • Genetic Engineering*
  • Humans
  • Neutralization Tests
  • Organ Specificity
  • Recombination, Genetic*
  • SARS-CoV-2 / genetics*
  • SARS-CoV-2 / physiology
  • Species Specificity
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology
  • Transduction, Genetic
  • Viral Vaccines
  • Virion / genetics

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines